Neurosense Therapeutics Ltd
NRSN
$1.02
Closing
▼-1.92%
1D
▲29.94%
YTD
NRSN
BBG0132WLC45
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $6.99/month
Market cap
$21.12M
Analysts' Rating
BUY
Price Target (Mean)
5.25
Total Analysts
2
P/E
Operating Margin
0.00%
Beta
Revenue Growth
0.00%
52 week high
$2.31
52 week low
$0.51
Div. Yield
%
EPS Growth
118.75
Company Profile
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company’s lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer’s disease and Parkinson’s disease
